Similarly, a whole-genome sequencing study of 46 ER-positive, pretreatment breast cancer samples from two neoadjuvant aromatase inhibitor therapy trials [ClinicalTrials.gov:NCT00084396, ClinicalTrials.gov:NCT00265759] did not reveal any ESR1 mutations [24]. Here, CYP19A1 is linked to breast carcinoma.